Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma.

Journal of gastroenterology and hepatology - 1 Sept 2012

Shin Hye Sun, Kim Seung Up, Park Jun Yong, Kim Do Young, Han Kwang-Hyub, Chon Chae Yoon, Baatarkhuu Oidov, Ahn Sang Hoon

Abstract excerpt

BACKGROUND AND AIM: Little information is available about the antiviral efficacy of lamivudine (LAM) and entecavir (ETV) in patients with hepatitis B virus (HBV)-related advanced hepatocellular carcinoma (HCC). Thus, we compared the antiviral efficacy of LAM and ETV in these patients. METHODS: Th...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Fetoproteins
Share to Carcinoma, Hepatocellular
Share to Chi-Square Distribution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guanine

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Kaplan-Meier Estimate

Share to Lamivudine

Source

Identifiers

PMID: 22497450
DOI: 10.1111/j.1440-1746.2012.07145.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22497450-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma.PMID 22497450Read ↗

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.Semantic proximity Read ↗

Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients.Semantic proximity Read ↗

Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation.Semantic proximity Read ↗

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.Semantic proximity Read ↗

Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.Semantic proximity Read ↗

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.Semantic proximity Read ↗

Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.Semantic proximity Read ↗

Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis.Semantic proximity Read ↗

Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B.Semantic proximity Read ↗

Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients.Semantic proximity Read ↗

Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.Semantic proximity Read ↗

A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.